

(IVa).

15. The compound of claim 1, wherein the compound is a compound of Formula (IVb) and q is 0, 1, 2, 3, or 4:



(IVb).

16. The compound of claim 1, wherein the compound is a compound of Formula (IVc) and q is 0, 1, 2, 3, or 4:



(IVc).

17. The compound of claim 1, wherein the compound of Formula (I) is selected from Compounds 1-390 of Table 1.

18. A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

19. A method of treating cancer, the method comprising administering a compound of claim 1 or a composition of claim 18 to a subject in need thereof.

20. The method of claim 19, wherein the cancer is selected from a cancer characterized by i) a low level of E-cadherin expression compared to a reference standard, ii) a high level of vimentin expression compared to a reference standard, or iii) a low or decreased level of pyruvate carboxylase expression.



(IVa).

15. The compound of claim 1, wherein the compound is a compound of Formula (IVb) and q is 0, 1, 2, 3, or 4:



(IVb).

16. The compound of claim 1, wherein the compound is a compound of Formula (IVc) and q is 0, 1, 2, 3, or 4:



(IVc).

17. The compound of claim 1, which is selected from the group consisting of:











































































































































































































































































































































































































































































































































































































































































































































































































































and



18. The compound of claim 1, which is



19. The compound of claim 1, which is



20. The compound of claim 1, which is



21. The compound of claim 1, which is



22. The compound of claim 1, which is



.

23. The compound of claim 1, which is



.

24. The compound of claim 1, which is



.

25. A pharmaceutical composition comprising a compound of Formula (I) according to any one of claims 1 to 24 and a pharmaceutically acceptable carrier.

26. Use of a compound of any one of claims 1 to 24 in the manufacture of a medicament for treating cancer in a subject in need thereof.

27. The use of claim 26, wherein the cancer is selected from a cancer characterized by i) a low level of E-cadherin expression compared to a reference standard, ii) a high level of vimentin expression compared to a reference standard, or iii) a low or decreased level of pyruvate carboxylase expression.

28. The use of claim 26 or 27, wherein said cancer is selected from non-small cell lung cancer, breast cancer, hepatocellular carcinoma, osteosarcoma, lipomas, chondrosarcoma, mesothelioma, colon cancer, renal cell carcinoma, acute myeloid leukemia (AML), melanoma and multiple myeloma.